Re-appointment of Cost Auditors for the FY 2026-27

Revenue declinedNet loss reportedExceptional itemNegative operating cash flowEmphasis of matterResults View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹540.00

prior close

₹522.85

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%-1.8% vs market

Pharmaceuticals peers, median of 161sector+0.4%-1.9% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.9

10m

+2.2

15m

+1.8

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.2-1.8+0.4-1.9

Next day

-4.3-0.1-4.2+0.1-4.4

-4.8-1.5-3.3-0.4-4.4

-3.7-1.0-2.7+0.0-3.8

-5.1-0.4-4.6+1.2-6.3

-3.1+0.6-3.7+2.1-5.1

-3.5+2.3-5.8+1.1-4.6

15d

+2.4+3.5-1.1+1.4+1.0

+14.6+5.6+9.1+2.2+12.4

+27.2+9.5+17.7+7.9+19.3

+34.2+13.3+21.0+8.1+26.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums Drugs reported Q4 and FY2026 results with revenue from operations of Rs. 13,487.36 million, a modest ~2.8% increase from Rs. 13,117.84 million in FY2025. However, profit after tax declined significantly by 30.6% to Rs. 1,116.40 million from Rs. 1,609.98 million in the prior year. EPS fell to Rs. 7.29 from Rs. 10.76. The Board recommended a final dividend of Rs. 1 per share plus a special dividend of Rs. 2 per share. Exceptional items of Rs. 65.19 million were recognized due to labour code changes and VDA arrears. The Income Tax Department had conducted a search and seizure in January 2025, and the company received show cause notices under section 158BC in May 2026, though no material adjustments were deemed necessary. Operating cash flow turned negative at Rs. 21.47 million versus positive Rs. 910.02 million in FY2025.

Likely market impact

Profit declined significantly despite flat revenue, indicating margin pressure. The negative operating cash flow and ongoing IT tax proceedings are concerns. However, dividend payouts and unchanged auditor opinion provide some stability.